The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure

International Journal of Cardiology

Volumn 212, Issue , 2016, Pages 187-189

  Lainscak, Mitja ^a,b   Coats, Andrew J S ^c,d  

^a General Hospital Celje   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ENALAPRIL; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE; VALSARTAN;

DISEASE SEVERITY; DRUG SAFETY; HEART FAILURE; HUMAN; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ENALAPRIL; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TREATMENT OUTCOME; VALSARTAN;

EID: 84962019412     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.02.130     Document Type: Editorial

References (25)

1. R.W. Schrier, and W.T. Abraham Hormones and hemodynamics in heart failure N. Engl. J. Med. 341 1999 577 585
2. V. Mollace, M. Gliozzi, A. Capuano, and F. Rossi Modulation of RAAS-natriuretic peptides in the treatment of heart failure: Old guys and newcomers Int. J. Cardiol. 2015 (in press)
3. F. Rossi, A. Mascolo, and V. Mollace The pathophysiological role of natriuretic peptide-RAAS cross-talk in heart failure Int. J. Cardiol. 2015 (in press)
4. J.J. McMurray, S. Adamopoulos, S.D. Anker, A. Auricchio, M. Böhm, K. Dickstein, and et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur. J. Heart Fail. 14 2012 803 869
5. K. Swedberg, M. Komajda, M. Böhm, J.S. Borer, I. Ford, A. Dubost-Brama, and et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study Lancet 376 2010 875 885
6. M. Gheorghiade, M. Böhm, S.J. Greene, G.C. Fonarow, E.F. Lewis, F. Zannad, and et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: The ASTRONAUT randomized trial JAMA 309 2013 1125 1135
7. S.D. Anker, and A.J. Coats How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH Int. J. Cardiol. 86 2002 123 130
8. D.B. Northridge, P.F. Currie, D.E. Newby, J.J. McMurray, M. Ford, N.A. Boon, and et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure Eur. J. Heart Fail. 1 1999 67 72
9. M. Packer, R.M. Califf, M.A. Konstam, H. Krum, J.J. McMurray, J.L. Rouleau, and et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE) Circulation 106 2002 920 926
10. M. Gori, M. Volterrani, M. Piepoli, and M. Senni Angiotensin receptor neprylisin inhibitor (ARNi): Clinical studies on a new class of drugs Int. J. Cardiol. 2015 (in press)
11. J.J. McMurray, M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, and et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N. Engl. J. Med. 371 2014 993 1004
12. J.J. McMurray, M. Packer, A.S. Desai, J. Gong, M. Lefkowitz, A.R. Rizkala, and et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) Eur. J. Heart Fail. 16 2014 817 825
13. J.G. Cleland, K. Swedberg, F. Follath, M. Komajda, A. Cohen-Solal, J.C. Aguilar, and et al. The EuroHeart failure survey programme - A survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis Eur. Heart J. 24 2003 442 463
14. A.P. Maggioni, S.D. Anker, U. Dahlström, G. Filippatos, P. Ponikowski, F. Zannad, and et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry Eur. J. Heart Fail. 15 10 Oct 2013 1173 1184
15. J.J. McMurray, M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Rizkala, and et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) Eur. J. Heart Fail. 15 2013 1062 1073
16. M. Lainscak, J.G. Cleland, M.J. Lenzen, F. Follath, M. Komajda, and K. Swedberg International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the EuroHeart failure survey Eur. J. Heart Fail. 9 2007 292 299
17. M. Volterrani, F. Iellamo, M. Senni, and M. Piepoli Therapeutic options of ARNi's in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition by ARNi's Int. J. Cardiol. 2015 (in press)
18. T. Roblek, K. Trobec, A. Mrhar, and M. Lainscak Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease Arch. Med. Sci. 10 2014 920 932
19. T. Roblek, T. Vaupotic, A. Mrhar, and M. Lainscak Drug-drug interaction software in clinical practice: A systematic review Eur. J. Clin. Pharmacol. 71 2015 131 142
20. T. Roblek, A. Deticek, B. Leskovar, S. Suskovic, M. Horvat, A. Belic, and et al. Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial Int. J. Cardiol. 203 2016 647 652
21. G.M. Rosano, B. Lewis, S. Agewall, S. Wassmann, C. Vitale, H. Schmidt, and et al. Gender differences in the effect of cardiovascular drugs: A position document of the Working Group on Pharmacology and Drug Therapy of the ESC Eur. Heart J. 36 2015 2677 2680
22. C. Bavishi, F.H. Messerli, B. Kadosh, L.M. Ruilope, and K. Kario Role of neprilysin inhibitor combinations in hypertension: Insights from hypertension and heart failure trials Eur. Heart J. 36 2015 1967 1973
23. B. Muk, B. Szabo, M. Dekany, P. Bogyi, D. Vagany, Z.S. Majoros, and et al. The effect of treatment optimization on the suitability of ARNI among patients followed at a heart failure outpatient clinic Eur. Heart J. 36 Suppl. 1 2015 556
24. Y. Cavusoglu, H. Altay, A. Ekmekci, M. Eren, M.S. Kucukoglu, S. Nalbantgil, and et al. Practical approaches for the treatment of chronic heart failure: Frequently asked questions, overlooked points and controversial issues in current clinical practice Anatol. J. Cardiol. 15 Suppl. 2 2015 1 60
25. https://clinicaltrials.gov/ct2/show/study/NCT01920711?term=paragon&rank=4&show-locs=Y#locn, (last viewed 21.12.2015)